Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
ISIN : CNE100004BN8
Share Class Description:
SHSE:688505: Class ACompare
Compare
Traded in other countries / regions
688505.China01349.Hong KongFDY.Germany IPO Date
2020-06-19Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 69.2 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.5 | |||||
| Interest Coverage | 33.47 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 7.42 | |||||
| Beneish M-Score | -1.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.4 | |||||
| 3-Year EBITDA Growth Rate | -23.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.5 | |||||
| 3-Year Book Growth Rate | 2.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.79 | |||||
| 9-Day RSI | 55.13 | |||||
| 14-Day RSI | 50.54 | |||||
| 6-1 Month Momentum % | -26.6 | |||||
| 12-1 Month Momentum % | -22.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | |||||
| Quick Ratio | 3.62 | |||||
| Cash Ratio | 2.37 | |||||
| Days Inventory | 554.34 | |||||
| Days Sales Outstanding | 595.68 | |||||
| Days Payable | 101.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.9 | |||||
| Dividend Payout Ratio | 0.8 | |||||
| 3-Year Dividend Growth Rate | -2 | |||||
| Forward Dividend Yield % | 0.9 | |||||
| 5-Year Yield-on-Cost % | 1.54 | |||||
| Shareholder Yield % | 2.26 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.12 | |||||
| Operating Margin % | 12.67 | |||||
| Net Margin % | 12.26 | |||||
| FCF Margin % | -8.52 | |||||
| ROE % | 1.72 | |||||
| ROA % | 1.34 | |||||
| ROIC % | 4.02 | |||||
| ROC (Joel Greenblatt) % | 6.74 | |||||
| ROCE % | 1.48 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 70 | |||||
| PE Ratio without NRI | 88.51 | |||||
| Shiller PE Ratio | 12.42 | |||||
| Price-to-Owner-Earnings | 32.17 | |||||
| PS Ratio | 6.45 | |||||
| PB Ratio | 0.91 | |||||
| Price-to-Tangible-Book | 0.95 | |||||
| Price-to-Operating-Cash-Flow | 30.02 | |||||
| EV-to-EBIT | 133.57 | |||||
| EV-to-EBITDA | 133.57 | |||||
| EV-to-Revenue | 14.4 | |||||
| EV-to-FCF | -166.85 | |||||
| Price-to-Projected-FCF | 0.77 | |||||
| Price-to-DCF (Earnings Based) | 7.7 | |||||
| Price-to-Graham-Number | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 1.58 | |||||
| Price-to-Net-Cash | 3.17 | |||||
| Earnings Yield (Greenblatt) % | 0.75 | |||||
| FCF Yield % | -0.46 | |||||
| Forward Rate of Return (Yacktman) % | -3.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 327.906 | ||
| EPS (TTM) (Â¥) | 0.11 | ||
| Beta | 1.11 | ||
| Volatility % | 30.24 | ||
| 14-Day RSI | 50.54 | ||
| 14-Day ATR (Â¥) | 0.253069 | ||
| 20-Day SMA (Â¥) | 7.3315 | ||
| 12-1 Month Momentum % | -22.94 | ||
| 52-Week Range (Â¥) | 6.24 - 10.71 | ||
| Shares Outstanding (Mil) | 1,043 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Frequently Asked Questions
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505)'s stock price today?
The current price of SHSE:688505 is ¥7.70. The 52 week high of SHSE:688505 is ¥10.71 and 52 week low is ¥6.24.
When is next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505)?
The next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) is .
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) is 0.9% (As of Today), Highest Dividend Payout Ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) was 0.8. The lowest was 0.21. And the median was 0.39. The  Forward Dividend Yield % of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) is 0.9%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers